AR088701A1 - CARBOXAMIDE AND UREA DERIVATIVES BASED ON PIRAZOLILO, SUBSTITUTED, CONTAINING A FENILE PORTION REPLACED WITH A GROUP CONTAINING N AS LIGANDOS OF THE VANILLOIDE RECEIVER - Google Patents
CARBOXAMIDE AND UREA DERIVATIVES BASED ON PIRAZOLILO, SUBSTITUTED, CONTAINING A FENILE PORTION REPLACED WITH A GROUP CONTAINING N AS LIGANDOS OF THE VANILLOIDE RECEIVERInfo
- Publication number
- AR088701A1 AR088701A1 ARP120104203A ARP120104203A AR088701A1 AR 088701 A1 AR088701 A1 AR 088701A1 AR P120104203 A ARP120104203 A AR P120104203A AR P120104203 A ARP120104203 A AR P120104203A AR 088701 A1 AR088701 A1 AR 088701A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- group
- vanilloide
- pirazolilo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Composiciones farmacéuticas que contienen esos compuestos y también con esos compuestos para usarse en el tratamiento y/o profilaxis del dolor y enfermedades y/o trastornos adicionales. Reivindicación 1: Un compuesto de fórmula general (1), caracterizado porque R¹⁰¹, R¹⁰² y R¹⁰³ son, independientemente uno del otro, seleccionados del grupo que consiste de H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, CH₂-OH, CH₂CH₂-OH, CH₂-OCH₃, CH₂CH₂-OCH₃, OCFH₂, OCF₂H, OCF₃, OH, NH₂ , un alquilo C₁₋₄, un O-alquilo C₁₋₄, un NH-alquilo C₁₋₄, y un N(alquilo C₁₋₄)₂, donde el alquilo C₁₋₄ está en cada caso no sustituido; R² representa CF₃, un alquilo no sustituido C₁₋₄ ₐ ᵘₙ ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₆ no sustituido; R⁷ y R⁹ son, independientemente uno del otro, seleccionados del grupo que consiste de H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, OH, OCF₃, un alquilo C₁₋₄, y un O-alquilo C₁₋₄, donde el alquilo C₁₋₄ está en cada caso no sustituido; A denota N, CH o C(CH₃); q denota 0, 1 ó 2; R¹¹² representa un H o un alquilo C₁₋₄, el cual no está sustituido o mono-, di- o trisustituido con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste de F, Cl, Br, OH, =O y OCH₃; R¹¹³ representa un H, S(=O)₂-NH₂, un alquilo C₁₋₄ o un S(=O)₂-alquilo C₁₋₄, donde el alquilo C₁₋₄ está en cada caso no sustituido o mono-, di- o trisustituido con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste de F, Cl, Br, OH, =O y OCH₃, o -con la condición de que q es &Pharmaceutical compositions containing those compounds and also with those compounds for use in the treatment and / or prophylaxis of pain and diseases and / or additional disorders. Claim 1: A compound of the general formula (1), characterized in that R¹⁰¹, R¹⁰² and R¹⁰³ are, independently of each other, selected from the group consisting of H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, CH₂- OH, CH₂CH₂-OH, CH₂-OCH₃, CH₂CH₂-OCH₃, OCFH₂, OCF₂H, OCF₃, OH, NH₂, a C₁₋₄ alkyl, an O-C₁₋₄ alkyl, an NH-C₁₋₄ alkyl, and an N ( C₁₋₄) ₂ alkyl, where the C₁₋₄ alkyl is in each case unsubstituted; R² represents CF₃, an unsubstituted C₁₋₄ ₐ ᵘₙ ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₆ alkyl; R⁷ and R⁹ are, independently of each other, selected from the group consisting of H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, OH, OCF₃, a C₁₋₄ alkyl, and a C₁₋₄ O-alkyl , where the C₁₋₄ alkyl is in each case unsubstituted; A denotes N, CH or C (CH₃); q denotes 0, 1 or 2; R¹¹² represents an H or a C₁₋₄ alkyl, which is not substituted or mono-, di- or trisubstituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, OH, = O and OCH₃; R¹¹³ represents an H, S (= O) ₂-NH₂, a C₁₋₄ alkyl or an S (= O) ₂-C alquilo alkyl, where the C₁₋₄ alkyl is in each case unsubstituted or mono-, di - or trisubstituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, OH, = O and OCH₃, or - with the proviso that q is &
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11008913 | 2011-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR088701A1 true AR088701A1 (en) | 2014-06-25 |
Family
ID=47143123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104203A AR088701A1 (en) | 2011-11-09 | 2012-11-08 | CARBOXAMIDE AND UREA DERIVATIVES BASED ON PIRAZOLILO, SUBSTITUTED, CONTAINING A FENILE PORTION REPLACED WITH A GROUP CONTAINING N AS LIGANDOS OF THE VANILLOIDE RECEIVER |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2776399A1 (en) |
JP (1) | JP2014532742A (en) |
KR (1) | KR20140096351A (en) |
CN (1) | CN103906736A (en) |
AR (1) | AR088701A1 (en) |
AU (1) | AU2012334066A1 (en) |
BR (1) | BR112014010957A2 (en) |
CA (1) | CA2854935A1 (en) |
HK (1) | HK1202116A1 (en) |
IN (1) | IN2014KN00847A (en) |
MX (1) | MX2014005611A (en) |
TW (1) | TW201326134A (en) |
WO (1) | WO2013068462A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3224252B1 (en) * | 2014-11-24 | 2019-01-09 | Medifron Dbt Inc. | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii |
CN114920697A (en) * | 2022-05-16 | 2022-08-19 | 河南应用技术职业学院 | Heterocyclic group substituted indan propionamide compound and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999012910A1 (en) * | 1997-09-11 | 1999-03-18 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and plant disease control agent |
NZ593684A (en) * | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
JP5399262B2 (en) * | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | LXR and FXR modulators |
WO2008125342A2 (en) * | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
DE102007018151A1 (en) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
AR076753A1 (en) | 2009-05-07 | 2011-07-06 | Gruenenthal Chemie | DERIVATIVES OF CARBOXAMIDE AND UREA AROMATICS REPLACED AS LIGANDOS OF THE VANILLOID RECEIVER. |
MX2011011797A (en) * | 2009-05-07 | 2011-11-29 | Gruenenthal Gmbh | Substituted phenyllureas and phenylamides as vanilloid receptor ligands. |
KR20140093260A (en) * | 2011-11-09 | 2014-07-25 | 그뤼넨탈 게엠베하 | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands |
-
2012
- 2012-11-08 AR ARP120104203A patent/AR088701A1/en unknown
- 2012-11-08 EP EP12781341.8A patent/EP2776399A1/en not_active Withdrawn
- 2012-11-08 KR KR1020147015425A patent/KR20140096351A/en not_active Application Discontinuation
- 2012-11-08 CA CA2854935A patent/CA2854935A1/en not_active Abandoned
- 2012-11-08 CN CN201280055195.9A patent/CN103906736A/en active Pending
- 2012-11-08 JP JP2014540454A patent/JP2014532742A/en active Pending
- 2012-11-08 MX MX2014005611A patent/MX2014005611A/en not_active Application Discontinuation
- 2012-11-08 BR BR112014010957A patent/BR112014010957A2/en not_active IP Right Cessation
- 2012-11-08 TW TW101141482A patent/TW201326134A/en unknown
- 2012-11-08 WO PCT/EP2012/072141 patent/WO2013068462A1/en active Application Filing
- 2012-11-08 AU AU2012334066A patent/AU2012334066A1/en not_active Abandoned
- 2012-11-08 IN IN847KON2014 patent/IN2014KN00847A/en unknown
-
2015
- 2015-03-13 HK HK15102577.0A patent/HK1202116A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014005611A (en) | 2014-07-30 |
CN103906736A (en) | 2014-07-02 |
BR112014010957A2 (en) | 2017-06-06 |
AU2012334066A1 (en) | 2014-05-22 |
WO2013068462A1 (en) | 2013-05-16 |
HK1202116A1 (en) | 2015-09-18 |
EP2776399A1 (en) | 2014-09-17 |
JP2014532742A (en) | 2014-12-08 |
CA2854935A1 (en) | 2013-05-16 |
IN2014KN00847A (en) | 2015-10-02 |
KR20140096351A (en) | 2014-08-05 |
TW201326134A (en) | 2013-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591727A1 (en) | BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201690598A1 (en) | AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS | |
EA201790599A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS | |
CY1122601T1 (en) | GSK3 INHIBITORS AND METHODS OF USING THEREOF | |
EA201591753A1 (en) | 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS | |
EA201490272A1 (en) | NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASE INHIBITORS | |
EA201592068A1 (en) | INHANSER INHIBITORS ZESTE HOMOLOGIST 2 | |
EA201792421A1 (en) | AMIDO-SUBSTITUTED DERIVATIVES OF CYCLOGEXANE | |
EA202190619A1 (en) | ANTIVIRAL COMPOUNDS | |
ECSP15012804A (en) | ALCOXYPYRAZOLES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS | |
AR097325A1 (en) | RINGED PIRROLS | |
PE20151994A1 (en) | SWEET FLAVOR MODIFIER | |
EA201690844A1 (en) | GSK-3 INHIBITORS | |
EA201790576A1 (en) | Spirocyclic inhibitors of katepsin C | |
EA201591360A1 (en) | AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS | |
EA201491747A1 (en) | SUBSTITUTED PYRIDOPYRIMIDINE COMPOUNDS AND THEIR APPLICATION AS FLT3 INHIBITORS | |
EA201492170A1 (en) | NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR | |
MX2015008993A (en) | Triazine based radiopharmaceuticals and radioimaging agents. | |
EA201890331A1 (en) | PYRIDINODICARBOXAMIDES FOR APPLICATION AS BROMODOUM INHIBITORS AS | |
MX2015012111A (en) | Ship1 modulators and methods related thereto. | |
EA201790570A1 (en) | P2X7 MODULATORS | |
EA201891379A1 (en) | BLUTON THYROSIN KINASE INHIBITORS AND METHODS OF THEIR USE | |
CO2018007663A2 (en) | Indolinone compounds and their use in the treatment of fibrotic diseases | |
CU20150006A7 (en) | DERIVATIVES OF (PIPERIDIN-4-IL) PIPERAZINA-1-CARBOXAMIDE / CARBOXYLATE USEFUL AS RECEIVER ANTAGONISTS -H3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |